Company Overview and News
Inogen Inc.’s (INGN - Free Report) first-quarter 2018 results are scheduled for release on Apr 30, after the market closes. A broadening Long-term Oxygen Therapy (“LTOT”) market, inherent benefits of Portable Oxygen Concentrators (“POC”) over traditional delivery model, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts.
REUTERS: Medical technology company Inogen Inc on Friday disclosed a data breach via an employee email account that resulted in personal information belonging to its rental customers and its own non-public financial information being accessed.
(Reuters) - Medical technology company Inogen Inc on Friday disclosed a data breach via an employee email account that resulted in personal information belonging to its rental customers and its own non-public financial information being accessed.
April 13 (Reuters) - Medical technology company Inogen Inc on Friday disclosed that one of its employee’s email accounts was breached and personal information belonging to its rental customers was accessed as well as its own non-public financial information.
ingn-s8.htm As filed with the Securities and Exchange Commission on February 28, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT Under The Securities Act of 1933 Inogen, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of incorporation or organization) (I.R.
Inogen, Inc. (INGN - Free Report) reported adjusted fourth-quarter earnings of 31 cents per share, outpacing the Zacks Consensus Estimate by 47.6%. Earnings increased 24% on a year-over-year basis.
Good afternoon and welcome to the Inogen 2017 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation there will be an opportunity to ask questions. [Operator Instructions]. Please note, this event is being recorded. I would now like to turn the conference over to Matt Bacso, Investor Relations Manager. Please go ahead.
The Q4 earnings season is approaching its end with more than 80% of the S&P 500 companies having released their quarterly earnings. Most of the companies have incurred big one-time charges related to the change in tax law this time around. The gap between adjusted operating earnings and reported earnings is in fact the widest in recent years. The MedTech space is also not immune to the trend.
ingn-8k_20180227.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2018 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-36309 33-0989359 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET